Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Nicholas Stong, María Ortiz-Estévez, Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Hervé Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (13): 1574–1583.

https://doi.org/10.1182/blood.2022016212

Published: 2023

Includes: Supplemental data

Journal Articles

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Naser Ansari-Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, Maria Ortiz Estevez, Konstantinos Mavrommatis, Brian Walker, Gareth Morgan, Nikhil Munshi, Herve Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (6): 620–633.

https://doi.org/10.1182/blood.2022017010

Published: 2023

Includes: Supplemental data

Journal Articles

Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3548–3550.

https://doi.org/10.1182/blood-2022-170228

Published: 2022

Journal Articles

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Mohammad Kazeroun, Kubra Karagoz, Ann Polonskaia, Mirian Salazar, Evie Fitzsimons, Korsuk Sirinukunwattana, Selina Chavda, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William Pierceall, Daniel Royston, Kwee Yong, Karthik Ramasamy, Paresh Vyas, Anjan Thakurta

Blood (2022) 140 (16): 1816–1821.

https://doi.org/10.1182/blood.2022015909

Published: 2022

Includes: Supplemental data

Journal Articles

Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination

Aarif Ahsan, Ann Polonskaia, Chih-Chao Hsu, Chad C Bjorklund, Maria Ortiz Estevez, Fadi Towfic, Nizar J. Bahlis, Michael Pourdehnad, Erin Flynt, Aarif Ahsan, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2658.

https://doi.org/10.1182/blood-2021-150641

Published: 2021

Journal Articles

Location of the t(4;14) Translocation Breakpoint Identifies a Subset of Newly-Diagnosed Multiple Myeloma Patients with Poor Prognosis

Nicholas Stong, Maria Ortiz, Fadi Towfic, William Pierceall, Erin Flynt, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 2681.

https://doi.org/10.1182/blood-2021-151094

Published: 2021

Journal Articles

Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients

Sarah Gooding, Naser Ansari-Pour, Mohammad H Kazeroun, Kubra Karagoz, Mirian Angulo Salazar, Evelyn Fitzsimons, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William E. Pierceall, Kwee Yong, Paresh Vyas, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 458.

https://doi.org/10.1182/blood-2021-150166

Published: 2021

Journal Articles

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Sarah Gooding, Naser Ansari-Pour, Fadi Towfic, María Ortiz Estévez, Philip P. Chamberlain, Kao-Tai Tsai, Erin Flynt, Marissa Hirst, Dan Rozelle, Paula Dhiman, Paola Neri, Karthik Ramasamy, Nizar Bahlis, Paresh Vyas, Anjan Thakurta

Blood (2021) 137 (2): 232–237.

https://doi.org/10.1182/blood.2020007081

Published: 2021

Includes: Supplemental data

Journal Articles

Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma

Nicholas J. Boddicker, PhD, Pinkal Desai, MDMPH, Mithun Vinod Shah, MD PhD, Vivekananda Sarangi, Matthew J. Maurer, MS, Elliot J. Cahn, Peter Martin, FRCPC, MD MS, Brian K. Link, MD, Thomas E. Witzig, MD, Andrew L. Feldman, MD, Grzegorz S. Nowakowski, MD, Thomas M. Habermann, MD, Susan L. Slager, PhD, C. Chris Huang, PhD, Fadi Towfic, PhD, Yan Asmann, PhD, Anita K Gandhi, PhD, Anne J. Novak, PhD, James R. Cerhan, MD PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-141726

Published: 2020

Journal Articles

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Alberto Risueño, Patrick R. Hagner, Fadi Towfic, Celia Fontanillo, Amira Djebbari, Joel S. Parker, Clifton P. Drew, Grzegorz S. Nowakowski, Matthew J. Maurer, James R. Cerhan, Xin Wei, Yan Ren, Chung-Wein Lee, Suzana Couto, Maria Wang, Michael Pourdehnad, Anita K. Gandhi, Matthew W. B. Trotter

Blood (2020) 135 (13): 1008–1018.

https://doi.org/10.1182/blood.2019002414

Published: 2020

Includes: Supplemental data

Journal Articles

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Sarah Gooding, FRCPath,MRCP,MBBChir, Naser Ansari-Pour, PhD, Fadi Towfic, PhD, Maria Ortiz, Dan Rozelle, PhD, Victoria Zadorozhny, Michael Amatangelo, Erin Flynt, Kao-Tai Tsai, Paola Neri, MD PhD, Nizar Bahlis, MD, Paresh Vyas, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 1793.

https://doi.org/10.1182/blood-2019-126828

Published: 2019

Journal Articles

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Blood (2019) 134 (Supplement_1): 919.

https://doi.org/10.1182/blood-2019-123694

Published: 2019

Journal Articles

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Blood (2019) 134 (Supplement_1): 923.

https://doi.org/10.1182/blood-2019-122756

Published: 2019

Journal Articles

Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers

Fadi Towfic, PhD, Naser Ansari-Pour, PhD, Maria Ortiz, Sarah Gooding, MD PhD, Dan Rozelle, PhD, Victoria Zadorozhny, Konstantinos Mavrommatis, PhD, Sneh Lata, PhD, Nicholas Stong, PhD, Sitharthan Kamalakaran, PhD, Kao-Tai Tsai, Erin Flynt, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 365.

https://doi.org/10.1182/blood-2019-124939

Published: 2019

Journal Articles

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Maria Ortiz, Fadi Towfic, PhD, Erin Flynt, Nicholas Stong, PhD, Sneh Lata, PhD, Dharanya Sampath, Dan Rozelle, PhD, Matthew Trotter, PhD, Jill Corre, PharmD, PhD, Hervé Avet-Loiseau, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 366.

https://doi.org/10.1182/blood-2019-128907

Published: 2019

Journal Articles

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Patrick R. Hagner, PhD, Hsiling Chiu, MS, Vivek S. Chopra, PhD, Martino S. Colombo, PhD, Nisha Patel, PhD, Maria Ortiz, Remco S. Loos, PhD, Fadi Towfic, PhD, Michelle Waldman, MS, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 306.

https://doi.org/10.1182/blood-2019-126681

Published: 2019

Journal Articles

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Blood (2019) 134 (Supplement_1): 4370.

https://doi.org/10.1182/blood-2019-127362

Published: 2019

Journal Articles

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

C. Chris Huang, PhD, Yumi Nakayama, PhD, Matthew Stokes, PhD, Fadi Towfic, PhD, chung-Wein Lee, Yan Ren, Mathieu Marella, PhD, Maria Wang, Patrick R. Hagner, PhD, Suzana Couto, Kathryn Newhall, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 2797.

https://doi.org/10.1182/blood-2019-123691

Published: 2019

Journal Articles

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

Anjan Thakurta, Maria Ortiz, Pedro Blecua, Fadi Towfic, Jill Corre, Natalya V. Serbina, Erin Flynt, Zhinuan Yu, Zhihong Yang, Antonio Palumbo, Meletios A. Dimopoulos, Norma C. Gutierrez, Hartmut Goldschmidt, Pieter Sonneveld, Herve Avet-Loiseau

Blood (2019) 133 (11): 1217–1221.

https://doi.org/10.1182/blood-2018-10-880831

Published: 2019

Includes: Supplemental data

Journal Articles

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Nikolaos Ioannou, PhD MSc, BSc, Patrick R. Hagner, PhD, Fadi Towfic, PhD, Anita K. Gandhi, PhD, Kostas Stamatopoulos, MD PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Anna Vardi, MD PhD, Alan G. Ramsay, BSc,MSc,PhD

Blood (2018) 132 (Supplement 1): 237.

https://doi.org/10.1182/blood-2018-99-111605

Published: 2018

NARROW

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma

Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination

Location of the t(4;14) Translocation Breakpoint Identifies a Subset of Newly-Diagnosed Multiple Myeloma Patients with Poor Prognosis

Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma

Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent

Genetic and Transcript Changesin Cereblon in IMiD-Treated Myeloma Patients

Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse

Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Profiling the Immune Tumor Microenvironment of Newly Diagnosed Diffuse Large B Cell Lymphoma Identifies Three Major Immune Infiltration Patterns

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only